Section 17O: Coverage for medical or drug treatments to correct or repair disturbances of body composition caused by HIV associated lipodystrophy syndrome
303 words·~1 min read·
/ma/part-i/title-iv/chapter-32a/17o·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
[Text of section added by 2016, 233, Sec. 1. See also, Section 17 O as added by 2016, 454, Sec. 1, below.]
Section 17O. Any coverage offered by the commission to an active or retired employee of the commonwealth insured under the group insurance commission shall provide coverage for medical or drug treatments to correct or repair disturbances of body composition caused by HIV associated lipodystrophy syndrome including, but not limited to, reconstructive surgery, such as suction assisted lipectomy, other restorative procedures and dermal injections or fillers for reversal of facial lipoatrophy syndrome.
Coverage shall be subject to a statement from a treating provider that the treatment is necessary for correcting, repairing or ameliorating the effects of HIV associated lipodystrophy syndrome. The benefits in this section shall not be subject to any greater deductible, coinsurance, copayments or out-of-pocket limits than any other benefit provided by the commission.
Chapter 32A: Section 17O. Coverage for refills of prescription eye drops
[Text of section added by 2016, 454, Sec. 1. See also, Section 17O added by 2016, 233, Sec. 1, above.]
Section 17O. Coverage offered by the commission to an active or retired employee of the commonwealth insured through the group insurance commission that provides coverage for prescription eye drops shall provide coverage for refills of prescription eye drops in accordance with the Medicare Part D guidelines on early refills of topical ophthalmic products when:
(i)the prescribing health care practitioner indicates on the original prescription that additional quantities of the prescription eye drops are needed;
(ii)the refill requested by the insured does not exceed the number of additional quantities indicated on the original prescription by the prescribing health care practitioner; and
(iii)the prescription eye drops prescribed by the health care practitioner are a covered benefit under the policy or contract of the insured.